Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Michael Lewiecki

Showing results (41-50 of 253) with videos related to

Pageof 26
Sort By:
Expert Opinion on Biological Therapy|September 23, 2006
RANK ligand inhibition with denosumab for the management of osteoporosisE Michael Lewiecki
Endocrinology and Metabolism Clinics of North America|May 23, 2021
Assessment of Skeletal Strength: Bone Density Testing and BeyondE Michael Lewiecki
Current Osteoporosis Reports|January 15, 2022
Evaluating Patients for Secondary Causes of OsteoporosisE Michael Lewiecki
Endocrinology and Metabolism (Seoul, Korea)|March 24, 2021
Operationalizing Treat-to-Target for OsteoporosisE Michael Lewiecki
Drugs|April 21, 2011
Safety of long-term bisphosphonate therapy for the management of osteoporosisE Michael Lewiecki
Current Medical Research and Opinion|June 15, 2011
Combination therapy: the Holy Grail for the treatment of postmenopausal osteoporosis?E Michael Lewiecki
Current Osteoporosis Reports|April 29, 2010
Benefits and limitations of bone mineral density and bone turnover markers to monitor patients treated for osteoporosisE Michael Lewiecki
Current Osteoporosis Reports|August 30, 2008
Vertebroplasty and kyphoplasty updateE Michael Lewiecki
Women'S Health (London, England)|October 7, 2009
Denosumab: a promising drug for the prevention and treatment of osteoporosisE Michael Lewiecki
Drug, Healthcare and Patient Safety|January 27, 2012
Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosisE Michael Lewiecki
Pageof 26

Showing results (41-50 of 253) with videos related to

Sort By:
Pageof 26
Expert Opinion on Biological Therapy|September 23, 2006
RANK ligand inhibition with denosumab for the management of osteoporosisE Michael Lewiecki
Endocrinology and Metabolism Clinics of North America|May 23, 2021
Assessment of Skeletal Strength: Bone Density Testing and BeyondE Michael Lewiecki
Current Osteoporosis Reports|January 15, 2022
Evaluating Patients for Secondary Causes of OsteoporosisE Michael Lewiecki
Endocrinology and Metabolism (Seoul, Korea)|March 24, 2021
Operationalizing Treat-to-Target for OsteoporosisE Michael Lewiecki
Drugs|April 21, 2011
Safety of long-term bisphosphonate therapy for the management of osteoporosisE Michael Lewiecki
Current Medical Research and Opinion|June 15, 2011
Combination therapy: the Holy Grail for the treatment of postmenopausal osteoporosis?E Michael Lewiecki
Current Osteoporosis Reports|April 29, 2010
Benefits and limitations of bone mineral density and bone turnover markers to monitor patients treated for osteoporosisE Michael Lewiecki
Current Osteoporosis Reports|August 30, 2008
Vertebroplasty and kyphoplasty updateE Michael Lewiecki
Women'S Health (London, England)|October 7, 2009
Denosumab: a promising drug for the prevention and treatment of osteoporosisE Michael Lewiecki
Drug, Healthcare and Patient Safety|January 27, 2012
Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosisE Michael Lewiecki
Pageof 26